Opdualag (nivolumab/relatlimab-rmbw)

P1/2, N=24, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed

P2, N=20, Active, not recruiting, Melanoma Institute Australia | Recruiting --> Active, not recruiting

P2, N=43, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting

P1, N=67, Terminated, TriSalus Life Sciences, Inc. | Active, not recruiting --> Terminated; The decision was made to terminate the study after the completion of Phase 1 enrollment and not proceed with Phase 2. Trial termination was not due to patient safety or data concerns.

The absence of macroscopic tumor and reduced peripheral LAG-3+ T cells may explain the lack of added benefit of nivolumab plus relatlimab over nivolumab in resected versus metastatic melanoma. ClinicalTrials.gov identifier: NCT05002569 .

Based on the hypothetical drug profile presented in the DCE, the fixed dose combination of nivolumab and relatlimab was the preferred regimen in the metastatic disease setting while either pembrolizumab or nivolumab were preferred in the adjuvant setting.Our study highlights the importance of considering patients' prioritization of treatment efficacy as the primary factor when making decisions about melanoma care, both in the adjuvant and metastatic settings. Although efficacy and safety were attributed to have relatively similar importance for treatment preference in the adjuvant setting, patients with more advanced disease or those carrying the BRAF mutation placed heightened emphasis on treatment efficacy.

P2, N=30, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2026 --> Jul 2028 | Trial primary completion date: Jul 2025 --> Jul 2028

This analysis demonstrated TFS benefit during the 48 months since initiating nivolumab plus relatlimab compared with nivolumab alone in patients with advanced melanoma. A direct comparison between nivolumab plus relatlimab and nivolumab plus ipilimumab is needed to determine the differences between the regimens in TFS and those in traditional endpoints.

P2, N=60, Recruiting, Stanford University | Not yet recruiting --> Recruiting

P2, N=30, Recruiting, University of California, San Diego | Not yet recruiting --> Recruiting

P3, N=1000, Recruiting, Bristol-Myers Squibb | Trial completion date: Nov 2033 --> Aug 2032

P3, N=770, Terminated, Bristol-Myers Squibb | Active, not recruiting --> Terminated; Inability to meet protocol objectives